Latest Financials News

Lithium Universe Limited has secured global rights to a breakthrough solar panel recycling technology that promises to unlock vast reserves of critical minerals, while advancing its Québec lithium refinery with robust financials and strategic partnerships.

Amplia Therapeutics reports encouraging ACCENT trial results for its FAK inhibitor narmafotinib, including rare complete responses in pancreatic cancer, alongside a $27.5 million capital raise to fund ongoing clinical development.

Western Mines Group has announced a landmark Mineral Resource Estimate for its Mulga Tank project, defining Australia’s largest nickel sulphide deposit with over 5.3 million tonnes of contained nickel. The company has secured government grants and raised capital to accelerate drilling and metallurgical testing.

Vection Technologies capped FY25 with its highest monthly order intake ever, driven by defence and AI/XR contracts, while posting positive pro-forma cash flow despite payment timing issues.

Fluence Corporation reports a robust 64.7% revenue increase in H1 2025, driven by strategic focus on higher-margin Smart Product Solutions and recurring revenue streams. The company maintains its FY2025 guidance, supported by a strong backlog and progress on a major Ivory Coast water project.

Silver Mines Limited progresses regulatory approvals for its flagship Bowdens Silver Project in NSW while acquiring promising US assets, enhancing its exploration pipeline with minimal upfront costs.

Alexium International Group faced a tough FY25 with declining sales amid a soft US mattress market but is poised for growth in FY26 thanks to technological advances and strategic funding support.

INOVIQ Limited reports breakthrough results for its ovarian cancer screening test achieving perfect early-stage detection, alongside promising advances in its CAR-exosome cancer therapy program.

Fluence Corporation Limited reported a positive net operating cash flow of US$5.1 million for Q2 2025, boosting its cash reserves to US$12.7 million and maintaining solid liquidity through revolving credit and loan facilities.

Lotus Resources is on track to restart uranium production at its Kayelekera project in Malawi by Q3 2025, backed by binding offtake contracts covering nearly 4 million pounds of uranium and a robust cash position.

Nyrada reports successful completion of five cohorts in its Phase I trial of Xolatryp with no safety concerns, alongside compelling preclinical neuro- and cardioprotective data. A Phase IIa trial targeting heart attack patients is slated for early 2026.

Cazaly Resources advances its Goongarrie Gold Project with promising high-grade drill results and identifies a new target area, while maintaining a solid cash position at the end of June 2025.